Concepedia
Statistics
Publications
17
Citations
1.7K
H-Index
Active since
1994
Affiliations
Emory University(Current)
Johns Hopkins University
The University of Texas MD Anderson Cancer Center
Novartis (United States)
Novartis Institutes for BioMedical Research
Kenneth Crawford is an author at Emory University specializing in drug discovery, pharmacology, and medicine.
Publications per year
1994–2020
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Konstantinos J. Mavrakis, E. Robert McDonald, Michael R. Schlabach et al. · Science · 2016 · 580 citations
Medicine, Cancer Biology, Oncology +16
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew T. Burger, Sabina Pecchi, Allan S. Wagman et al. · ACS Medicinal Chemistry Letters · 2011 · 251 citations · Full text
Pharmacy, Oncology, Pharmacology +13
Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
Mallé Jurima‐Romet, Kenneth Crawford, Terry D. Cyr et al. · Drug Metabolism and Disposition · 1994 · 162 citations
Medicine, Pharmacokinetics, Pharmacology +17
Several Convenient Methods for the Synthesis of 2-Amido Substituted Furans
Albert Padwa, Kenneth Crawford, Paitoon Rashatasakhon et al. · The Journal of Organic Chemistry · 2003 · 92 citations
Natural Sciences, Chemistry, Medicinal Chemistry +17
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Kelli‐Ann Monaco, Scott Delach, Jing Yuan et al. · Clinical Cancer Research · 2020 · 88 citations · Full text
Medicine, Oncology, Pharmacology +17
1–5 of 17